BG64819B1 - Комбиниране на тетрахидропиридини и средства, инхибиращи ацетилхолинестераза, за лечение на сенилнадеменция от алцхаймеров тип - Google Patents

Комбиниране на тетрахидропиридини и средства, инхибиращи ацетилхолинестераза, за лечение на сенилнадеменция от алцхаймеров тип Download PDF

Info

Publication number: BG64819B1
Authority: BG; Bulgaria
Prior art keywords: tetrahydropyridine; compound; pharmaceutically acceptable; composition according; trifluoromethylphenyl
Prior art date: 1997-11-14

Application number

BG104428A

Other languages

Bulgarian (bg)

English (en)

Other versions

BG104428A (en

Inventor

Jean-Pierre Maffrand

Philippe Soubrie

Jean-Paul Terranova

Original Assignee

Sanofi-Synthelabo

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-11-14

Filing date

2000-05-11

Publication date

2006-05-31

1997-11-14 Priority claimed from FR9714324A external-priority patent/FR2771006B1/fr

1997-11-14 Priority claimed from FR9714322A external-priority patent/FR2771007B1/fr

2000-05-11 Application filed by Sanofi-Synthelabo filed Critical Sanofi-Synthelabo

2001-08-31 Publication of BG104428A publication Critical patent/BG104428A/xx

2006-05-31 Publication of BG64819B1 publication Critical patent/BG64819B1/bg

Links

208000024827 Alzheimer disease Diseases 0.000 title claims abstract description 21
206010039966 Senile dementia Diseases 0.000 title claims abstract description 18
102000012440 Acetylcholinesterase Human genes 0.000 title 1
108010022752 Acetylcholinesterase Proteins 0.000 title 1
229940022698 acetylcholinesterase Drugs 0.000 title 1
150000003839 salts Chemical class 0.000 claims abstract description 37
150000001875 compounds Chemical class 0.000 claims abstract description 32
239000000203 mixture Substances 0.000 claims abstract description 30
-1 4-substituted-1,2,3,6-tetrahydropyridin Chemical class 0.000 claims abstract description 19
238000011282 treatment Methods 0.000 claims abstract description 14
238000002636 symptomatic treatment Methods 0.000 claims abstract description 12
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 9
238000002360 preparation method Methods 0.000 claims abstract description 8
CNEWKIDCGDXBDE-UHFFFAOYSA-N 1-[2-(4-phenylphenyl)ethyl]-4-[3-(trifluoromethyl)phenyl]-3,6-dihydro-2h-pyridine Chemical compound FC(F)(F)C1=CC=CC(C=2CCN(CCC=3C=CC(=CC=3)C=3C=CC=CC=3)CC=2)=C1 CNEWKIDCGDXBDE-UHFFFAOYSA-N 0.000 claims abstract description 4
ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 claims description 28
239000004480 active ingredient Substances 0.000 claims description 25
WJJYZXPHLSLMGE-UHFFFAOYSA-N xaliproden Chemical compound FC(F)(F)C1=CC=CC(C=2CCN(CCC=3C=C4C=CC=CC4=CC=3)CC=2)=C1 WJJYZXPHLSLMGE-UHFFFAOYSA-N 0.000 claims description 19
239000000544 cholinesterase inhibitor Substances 0.000 claims description 17
229960003530 donepezil Drugs 0.000 claims description 13
229960001685 tacrine Drugs 0.000 claims description 10
229940100578 Acetylcholinesterase inhibitor Drugs 0.000 claims description 9
YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical group C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 claims description 9
239000003814 drug Substances 0.000 claims description 7
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 5
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 claims description 4
229960004136 rivastigmine Drugs 0.000 claims description 4
FTAHXMZRJCZXDL-UHFFFAOYSA-N 3-piperideine Chemical compound C1CC=CCN1 FTAHXMZRJCZXDL-UHFFFAOYSA-N 0.000 claims description 3
125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 2
206010012289 Dementia Diseases 0.000 abstract description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
201000010099 disease Diseases 0.000 description 8
241000700159 Rattus Species 0.000 description 5
WVHBEIJGAINUBW-UHFFFAOYSA-N Xaliproden hydrochloride Chemical compound Cl.FC(F)(F)C1=CC=CC(C=2CCN(CCC=3C=C4C=CC=CC4=CC=3)CC=2)=C1 WVHBEIJGAINUBW-UHFFFAOYSA-N 0.000 description 5
125000000217 alkyl group Chemical group 0.000 description 5
230000000694 effects Effects 0.000 description 5
108010025020 Nerve Growth Factor Proteins 0.000 description 4
229910052736 halogen Inorganic materials 0.000 description 4
150000002367 halogens Chemical class 0.000 description 4
125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 3
OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 3
229960004373 acetylcholine Drugs 0.000 description 3
125000003545 alkoxy group Chemical group 0.000 description 3
125000004453 alkoxycarbonyl group Chemical group 0.000 description 3
229940079593 drug Drugs 0.000 description 3
229910052739 hydrogen Inorganic materials 0.000 description 3
239000001257 hydrogen Substances 0.000 description 3
125000004356 hydroxy functional group Chemical group O* 0.000 description 3
230000015654 memory Effects 0.000 description 3
238000000034 method Methods 0.000 description 3
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
230000002195 synergetic effect Effects 0.000 description 3
239000003826 tablet Substances 0.000 description 3
OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 3
229960004528 vincristine Drugs 0.000 description 3
OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 3
125000006273 (C1-C3) alkyl group Chemical group 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
102000015336 Nerve Growth Factor Human genes 0.000 description 2
102000007072 Nerve Growth Factors Human genes 0.000 description 2
239000013543 active substance Substances 0.000 description 2
125000003282 alkyl amino group Chemical group 0.000 description 2
239000002775 capsule Substances 0.000 description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
230000000295 complement effect Effects 0.000 description 2
238000001816 cooling Methods 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
235000003599 food sweetener Nutrition 0.000 description 2
ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 2
150000002431 hydrogen Chemical class 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
230000003902 lesion Effects 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
229940053128 nerve growth factor Drugs 0.000 description 2
210000002569 neuron Anatomy 0.000 description 2
239000000843 powder Substances 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
229940044551 receptor antagonist Drugs 0.000 description 2
239000002464 receptor antagonist Substances 0.000 description 2
238000011084 recovery Methods 0.000 description 2
230000004036 social memory Effects 0.000 description 2
239000002904 solvent Substances 0.000 description 2
239000003765 sweetening agent Substances 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
KWDXGALCQUZREM-VKHMYHEASA-N (2s)-2-(methoxyamino)butanedioic acid Chemical compound CON[C@H](C(O)=O)CC(O)=O KWDXGALCQUZREM-VKHMYHEASA-N 0.000 description 1
HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 1
125000006529 (C3-C6) alkyl group Chemical group 0.000 description 1
125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 description 1
150000008083 1,2,3,6-tetrahydropyridines Chemical class 0.000 description 1
DNJYJMDQLURVBB-UHFFFAOYSA-N 2-(2-bromoethyl)naphthalene Chemical compound C1=CC=CC2=CC(CCBr)=CC=C21 DNJYJMDQLURVBB-UHFFFAOYSA-N 0.000 description 1
CWEHWZPCDBRUNO-WLHGVMLRSA-N 3-(1-benzylpiperidin-4-yl)-1-(2,3,4,5-tetrahydro-1h-1-benzazepin-8-yl)propan-1-one;(e)-but-2-enedioic acid Chemical compound OC(=O)\C=C\C(O)=O.C=1C=C2CCCCNC2=CC=1C(=O)CCC(CC1)CCN1CC1=CC=CC=C1 CWEHWZPCDBRUNO-WLHGVMLRSA-N 0.000 description 1
IFYKRMQORZOMNY-UHFFFAOYSA-N 4-[3-(trifluoromethyl)phenyl]-1,2,3,6-tetrahydropyridine Chemical compound FC(F)(F)C1=CC=CC(C=2CCNCC=2)=C1 IFYKRMQORZOMNY-UHFFFAOYSA-N 0.000 description 1
HLVVITIHAZBPKB-UHFFFAOYSA-N 9-amino-1,2,3,4-tetrahydroacridin-1-ol Chemical compound C1=CC=C2C(N)=C(C(O)CCC3)C3=NC2=C1 HLVVITIHAZBPKB-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
208000000044 Amnesia Diseases 0.000 description 1
208000031091 Amnestic disease Diseases 0.000 description 1
229920000858 Cyclodextrin Polymers 0.000 description 1
239000004097 EU approved flavor enhancer Substances 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
206010022998 Irritability Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 1
229940099433 NMDA receptor antagonist Drugs 0.000 description 1
PIJVFDBKTWXHHD-UHFFFAOYSA-N Physostigmine Natural products C12=CC(OC(=O)NC)=CC=C2N(C)C2C1(C)CCN2C PIJVFDBKTWXHHD-UHFFFAOYSA-N 0.000 description 1
241000978776 Senegalia senegal Species 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
RRGMXBQMCUKRLH-CTNGQTDRSA-N [(3ar,8bs)-3,4,8b-trimethyl-2,3a-dihydro-1h-pyrrolo[2,3-b]indol-7-yl] n-heptylcarbamate Chemical compound C12=CC(OC(=O)NCCCCCCC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C RRGMXBQMCUKRLH-CTNGQTDRSA-N 0.000 description 1
ILLGYRJAYAAAEW-QMMMGPOBSA-N abt-418 Chemical compound CN1CCC[C@H]1C1=CC(C)=NO1 ILLGYRJAYAAAEW-QMMMGPOBSA-N 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
125000004442 acylamino group Chemical group 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000000556 agonist Substances 0.000 description 1
125000004457 alkyl amino carbonyl group Chemical group 0.000 description 1
230000006986 amnesia Effects 0.000 description 1
230000002421 anti-septic effect Effects 0.000 description 1
229940064004 antiseptic throat preparations Drugs 0.000 description 1
229940039856 aricept Drugs 0.000 description 1
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
125000005111 carboxyalkoxy group Chemical group 0.000 description 1
125000004181 carboxyalkyl group Chemical group 0.000 description 1
239000000969 carrier Substances 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
230000001713 cholinergic effect Effects 0.000 description 1
230000003920 cognitive function Effects 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000011284 combination treatment Methods 0.000 description 1
125000000000 cycloalkoxy group Chemical group 0.000 description 1
125000006310 cycloalkyl amino group Chemical group 0.000 description 1
125000004981 cycloalkylmethyl group Chemical group 0.000 description 1
125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
230000007850 degeneration Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
229950010753 eptastigmine Drugs 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
235000019264 food flavour enhancer Nutrition 0.000 description 1
238000009472 formulation Methods 0.000 description 1
229960003980 galantamine Drugs 0.000 description 1
ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000008187 granular material Substances 0.000 description 1
125000005843 halogen group Chemical group 0.000 description 1
239000007902 hard capsule Substances 0.000 description 1
230000035876 healing Effects 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
ZUFVXZVXEJHHBN-UHFFFAOYSA-N hydron;1,2,3,4-tetrahydroacridin-9-amine;chloride Chemical compound [Cl-].C1=CC=C2C([NH3+])=C(CCCC3)C3=NC2=C1 ZUFVXZVXEJHHBN-UHFFFAOYSA-N 0.000 description 1
230000006872 improvement Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
238000002955 isolation Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
239000000463 material Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 1
229960004640 memantine Drugs 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
229960002216 methylparaben Drugs 0.000 description 1
229960001952 metrifonate Drugs 0.000 description 1
239000003094 microcapsule Substances 0.000 description 1
239000011859 microparticle Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
239000000472 muscarinic agonist Substances 0.000 description 1
239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 description 1
210000000653 nervous system Anatomy 0.000 description 1
230000004770 neurodegeneration Effects 0.000 description 1
208000015122 neurodegenerative disease Diseases 0.000 description 1
230000000626 neurodegenerative effect Effects 0.000 description 1
230000000324 neuroprotective effect Effects 0.000 description 1
239000002858 neurotransmitter agent Substances 0.000 description 1
230000000508 neurotrophic effect Effects 0.000 description 1
230000002276 neurotropic effect Effects 0.000 description 1
229960002715 nicotine Drugs 0.000 description 1
SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
239000000181 nicotinic agonist Substances 0.000 description 1
239000002664 nootropic agent Substances 0.000 description 1
230000001777 nootropic effect Effects 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
229960001697 physostigmine Drugs 0.000 description 1
PIJVFDBKTWXHHD-HIFRSBDPSA-N physostigmine Chemical compound C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C PIJVFDBKTWXHHD-HIFRSBDPSA-N 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
229960003415 propylparaben Drugs 0.000 description 1
GWHQHAUAXRMMOT-MBANBULQSA-N rivastigmine tartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 GWHQHAUAXRMMOT-MBANBULQSA-N 0.000 description 1
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
239000007901 soft capsule Substances 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
238000001694 spray drying Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
238000003756 stirring Methods 0.000 description 1
125000005504 styryl group Chemical group 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
NFACJZMKEDPNKN-UHFFFAOYSA-N trichlorfon Chemical compound COP(=O)(OC)C(O)C(Cl)(Cl)Cl NFACJZMKEDPNKN-UHFFFAOYSA-N 0.000 description 1
229950001843 velnacrine Drugs 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Biomedical Technology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

BG104428A 1997-11-14 2000-05-11 Комбиниране на тетрахидропиридини и средства, инхибиращи ацетилхолинестераза, за лечение на сенилнадеменция от алцхаймеров тип BG64819B1 (bg)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR9714324A FR2771006B1 (fr)	1997-11-14	1997-11-14	Association de principes actifs pour le traitement de la demence senile du type alzheimer
FR9714322A FR2771007B1 (fr)	1997-11-14	1997-11-14	Association de principes actifs pour le traitement de la demence senile du type alzheimer

Publications (2)

Publication Number	Publication Date
BG104428A BG104428A (en)	2001-08-31
BG64819B1 true BG64819B1 (bg)	2006-05-31

Family

ID=26233932

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG104428A BG64819B1 (bg)	1997-11-14	2000-05-11	Комбиниране на тетрахидропиридини и средства, инхибиращи ацетилхолинестераза, за лечение на сенилнадеменция от алцхаймеров тип

Country Status (27)

Country	Link
EP (1)	EP1030671A1 (pl)
JP (1)	JP2001523642A (pl)
KR (1)	KR100599350B1 (pl)
CN (1)	CN1243540C (pl)
AU (1)	AU743228B2 (pl)
BG (1)	BG64819B1 (pl)
BR (1)	BR9814035A (pl)
CA (1)	CA2309966A1 (pl)
CO (1)	CO4980891A1 (pl)
DZ (1)	DZ2649A1 (pl)
EA (1)	EA003255B1 (pl)
EE (1)	EE04235B1 (pl)
HU (1)	HUP0100098A3 (pl)
ID (1)	ID24933A (pl)
IL (2)	IL136122A0 (pl)
IS (1)	IS5482A (pl)
MY (1)	MY120461A (pl)
NO (1)	NO20002450L (pl)
NZ (1)	NZ504420A (pl)
OA (1)	OA11464A (pl)
PL (1)	PL194597B1 (pl)
SA (1)	SA98190747B1 (pl)
SK (1)	SK286040B6 (pl)
TR (1)	TR200001262T2 (pl)
TW (1)	TW585766B (pl)
UY (1)	UY25247A1 (pl)
WO (1)	WO1999025363A1 (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2003105830A1 (ja) *	2002-06-14	2003-12-24	富山化学工業株式会社	脳機能を改善する医薬組成物および脳機能を改善するための方法
US20060160079A1 (en) *	2002-08-07	2006-07-20	Lane Roger M	Methods for the treatment of dementia based on apo e genotype
CN1520818A (zh) *	2003-02-09	2004-08-18	ɽ��Ҷ��Ȼҩ��о��޹�˾	治疗老年性痴呆的胆碱酯酶抑制剂药物组合物
US8481565B2 (en)	2004-12-27	2013-07-09	Eisai R&D Management Co., Ltd.	Method for stabilizing anti-dementia drug
AU2015210852B2 (en)	2014-01-31	2019-01-24	Cognition Therapeutics, Inc.	Isoindoline compositions and methods for treating neurodegenerative disease
DK3634394T3 (da)	2017-05-15	2026-03-02	Cognition Therapeutics Inc	Sammensætninger til behandling af neurogenerative sygdomme
KR102224917B1 (ko)	2018-03-20	2021-03-09	(주)인벤티지랩	인지 장애 관련 질병의 예방 또는 치료용 약학적 조성물의 제조 방법 및 이의 제조 방법으로 제조된 인지 장애 관련 질병의 예방 또는 치료용 약학적 조성물
WO2019182319A1 (ko) *	2018-03-20	2019-09-26	(주)인벤티지랩	인지 장애 관련 질병의 예방 또는 치료용 약학적 조성물의 제조 방법 및 이의 제조 방법으로 제조된 인지 장애 관련 질병의 예방 또는 치료용 약학적 조성물
CN109265391B (zh) *	2018-11-13	2021-11-19	枣庄学院	联苯多取代1,2,5,6-四氢吡啶化合物及其合成方法与应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0458696A2 (fr) *	1990-05-22	1991-11-27	Sanofi	Utilisation d'une 1-(2-naphtyléthyl)-4-(3-trifluorométhylphényl)-1,2,3,6-tétrahydropyridine pour la préparation de médicaments destinés au traitement de troubles cérébraux et neuronaux
WO1997001536A1 (fr) *	1995-06-28	1997-01-16	Sanofi	4-aryl-1-phenylalkyl-1,2,3,6-tetrahydropyridines ayant une activite neurotrophique et neuroprotectrice

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5453428A (en) *	1991-02-14	1995-09-26	The Mount Sinai School Of Medicine Of The City Of New York	Method and composition for the treatment of apathy-amotivation syndrome
CA2213000A1 (en) *	1995-03-06	1996-09-12	Interneuron Pharmaceuticals, Inc.	Reduction of infarct volume using citicoline

1998
- 1998-10-26 CO CO98062479A patent/CO4980891A1/es unknown
- 1998-10-28 TW TW087117874A patent/TW585766B/zh not_active IP Right Cessation
- 1998-11-09 SK SK711-2000A patent/SK286040B6/sk unknown
- 1998-11-09 CN CNB988130947A patent/CN1243540C/zh not_active Expired - Fee Related
- 1998-11-09 JP JP2000520796A patent/JP2001523642A/ja not_active Withdrawn
- 1998-11-09 EA EA200000412A patent/EA003255B1/ru not_active IP Right Cessation
- 1998-11-09 WO PCT/FR1998/002384 patent/WO1999025363A1/fr not_active Ceased
- 1998-11-09 CA CA002309966A patent/CA2309966A1/en not_active Abandoned
- 1998-11-09 NZ NZ504420A patent/NZ504420A/en unknown
- 1998-11-09 TR TR2000/01262T patent/TR200001262T2/xx unknown
- 1998-11-09 BR BR9814035-3A patent/BR9814035A/pt not_active Application Discontinuation
- 1998-11-09 HU HU0100098A patent/HUP0100098A3/hu unknown
- 1998-11-09 AU AU11609/99A patent/AU743228B2/en not_active Ceased
- 1998-11-09 EP EP98954538A patent/EP1030671A1/fr not_active Withdrawn
- 1998-11-09 KR KR1020007005231A patent/KR100599350B1/ko not_active Expired - Fee Related
- 1998-11-09 ID IDW20000860A patent/ID24933A/id unknown
- 1998-11-09 EE EEP200000290A patent/EE04235B1/xx not_active IP Right Cessation
- 1998-11-09 PL PL98340500A patent/PL194597B1/pl not_active IP Right Cessation
- 1998-11-09 IL IL13612298A patent/IL136122A0/xx not_active IP Right Cessation
- 1998-11-11 DZ DZ980259A patent/DZ2649A1/xx active
- 1998-11-12 UY UY25247A patent/UY25247A1/es not_active IP Right Cessation
- 1998-11-14 MY MYPI98005180A patent/MY120461A/en unknown
- 1998-11-14 SA SA98190747A patent/SA98190747B1/ar unknown
2000
- 2000-05-09 IS IS5482A patent/IS5482A/is unknown
- 2000-05-11 NO NO20002450A patent/NO20002450L/no unknown
- 2000-05-11 BG BG104428A patent/BG64819B1/bg unknown
- 2000-05-12 OA OA1200000141A patent/OA11464A/en unknown
- 2000-05-14 IL IL136122A patent/IL136122A/en unknown

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0458696A2 (fr) *	1990-05-22	1991-11-27	Sanofi	Utilisation d'une 1-(2-naphtyléthyl)-4-(3-trifluorométhylphényl)-1,2,3,6-tétrahydropyridine pour la préparation de médicaments destinés au traitement de troubles cérébraux et neuronaux
WO1997001536A1 (fr) *	1995-06-28	1997-01-16	Sanofi	4-aryl-1-phenylalkyl-1,2,3,6-tetrahydropyridines ayant une activite neurotrophique et neuroprotectrice

Also Published As

Publication number	Publication date
PL194597B1 (pl)	2007-06-29
EP1030671A1 (fr)	2000-08-30
IL136122A (en)	2006-07-05
SA98190747B1 (ar)	2006-11-04
MY120461A (en)	2005-10-31
DZ2649A1 (fr)	2004-12-28
CA2309966A1 (en)	1999-05-27
IS5482A (is)	2000-05-09
JP2001523642A (ja)	2001-11-27
ID24933A (id)	2000-08-31
PL340500A1 (en)	2001-02-12
AU743228B2 (en)	2002-01-24
OA11464A (en)	2003-11-18
EA200000412A1 (ru)	2000-12-25
SK7112000A3 (en)	2000-10-09
KR100599350B1 (ko)	2006-07-12
EE200000290A (et)	2001-06-15
IL136122A0 (en)	2001-05-20
BR9814035A (pt)	2000-09-26
TW585766B (en)	2004-05-01
WO1999025363A1 (fr)	1999-05-27
CO4980891A1 (es)	2000-11-27
UY25247A1 (es)	2001-05-31
CN1243540C (zh)	2006-03-01
BG104428A (en)	2001-08-31
NO20002450D0 (no)	2000-05-11
NZ504420A (en)	2003-08-29
CN1285742A (zh)	2001-02-28
HUP0100098A3 (en)	2001-12-28
HUP0100098A2 (hu)	2001-07-30
NO20002450L (no)	2000-07-14
EE04235B1 (et)	2004-02-16
KR20010032099A (ko)	2001-04-16
AU1160999A (en)	1999-06-07
EA003255B1 (ru)	2003-02-27
TR200001262T2 (tr)	2001-01-22
SK286040B6 (sk)	2008-01-07

Publication	Publication Date	Title
DE60122928T2 (de)	2007-09-06	Therapeutische zusammensetzung von amlodipin und benazepril / benazeprilat
AU743609B2 (en)	2002-01-31	Use of cholinesterase inhibitors to treat disorders of attention
EP0216555B1 (en)	1992-09-02	Use of dioxopiperidine derivatives in the treatment of anxiety, for the reduction of chronic abnormally high brain levels of serotonin or 5-hydroxy-indoleacetic acid, and in the treatment of bacterial or viral infections
CA2690110A1 (en)	2009-01-22	Ampa receptor antagonists for neuropathic pain
MXPA02011610A (es)	2003-05-14	Combinacion de sustancia activa que contiene un opioide que tiene una estructura tipo fentanilo y cetamina.
EP2148673A1 (en)	2010-02-03	Cinnamide compounds for dementia
AU2004283425A1 (en)	2005-05-06	Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an acetylcholinesterase inhibitor
KR100599350B1 (ko)	2006-07-12	알츠하이머 치매와 같은 노인성 치매 치료용의 활성 성분들, 특히, 테트라히드로피리딘류 및 아세틸콜린에스테라아제 억제제의 배합물
US20050148614A1 (en)	2005-07-07	Combination of active ingredients for the treatment of senile dementia of the Alzheimer type
US20060287325A1 (en)	2006-12-21	Combinations of paroxetine and 2-(r)-(4-fluoro-2-methyl-phenyl)-4-(s)-((8as)-6-oxo-hexahydro-pyrrolo'1,2-a!-pyrazin-2-yl)-piperidine-1-carboxylicacid'1-(r)-(3,5-bis-trifluoromethyl-phenyl)-
US4797404A (en)	1989-01-10	Pharmaceutical preparation comprising co-dergocrine and a calcium antagonist
JP2002504134A (ja)	2002-02-05	疼痛を治療するためのドラフラジン類似体の使用
MXPA00004600A (en)	2001-05-07	Combination of active principles, in particular of tetrahydropyridins and acetylcholinesterase inhibiting agents, for treating senile dementia such as alzheimer dementia
CZ20001734A3 (cs)	2000-08-16	Farmaceutická kompozice a její použití
RS20060505A (sr)	2008-09-29	Kombinovani farmaceutski preparat za inhibiciju opadanja kognitivnih funkcija
US4363809A (en)	1982-12-14	Organic compounds
JPS6144816A (ja)	1986-03-04	組み合わせ生成物およびその調製方法
JP2003226642A (ja)	2003-08-12	眼疾患予防及び／又は治療薬
FR2771007A1 (fr)	1999-05-21	Association de principes actifs pour le traitement de la demence senile du type alzheimer